Drugs / JNJ-64300535
JNJ-64300535
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05123599 | Dec 2021 → Jul 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04736147 | Feb → Dec 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03463369 | Apr 2018 → Mar 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64300535 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03463369 ↗ |
| Known as | JNJ-0535 | “We aimed to assess safety and T-cell responses induced by JNJ-6430535 (JNJ-0535); a hepatitis B virus (HBV)-specific therapeutic DNA vaccine administered via...” PMID 41644953 ↗ Feb 2026 |
| Known as | JNJ-6430535 | “We aimed to assess safety and T-cell responses induced by JNJ-6430535 (JNJ-0535); a hepatitis B virus (HBV)-specific therapeutic DNA vaccine administered via...” PMID 41644953 ↗ Feb 2026 |
| Modality | Vaccine | “HBV-specific therapeutic DNA vaccine” PMID 41644953 ↗ Feb 2026 |
| Route | Intramuscular | “administered via electroporation-mediated intramuscular injection” PMID 41644953 ↗ Feb 2026 |